Defining the role of corticotropin releasing factor binding protein in alcohol consumption by Haass-Koffler, Carolina et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Haass-Koffler, C.L., Henry, A.T., Melkus, G, Simms, J.A., Naemmuddin,
M, Nielsen, C.K., Lasek, A.W., Magill, M, Schwandt, M.L., Momenan, R,
Hodgkinson, C.A., Bartlett, S.E., Swift, R.M., Bonci, A, & Leggio, L
(2016)
Defining the role of corticotropin releasing factor binding protein in alcohol
consumption.
Translational Psychiatry, 6(11).
This file was downloaded from: https://eprints.qut.edu.au/108520/
c© 2016 [please consult the authors]
This work is licensed under a Creative Commons Attribution 4.0 International License.
The images or other third party material in this article are included in the article’s Cre-
ative Commons license, unless indicated otherwise in the credit line; if the material is
not included under the Creative Commons license, users will need to obtain permission
from the license holder to reproduce the material. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/.
License: Creative Commons: Attribution 4.0
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
https://doi.org/10.1038/tp.2016.208
OPEN
ORIGINAL ARTICLE
Deﬁning the role of corticotropin releasing factor binding
protein in alcohol consumption
CL Haass-Kofﬂer1,2,3, AT Henry4, G Melkus5, JA Simms6, M Naemmuddin6, CK Nielsen6, AW Lasek7, M Magill3, ML Schwandt8,
R Momenan9, CA Hodgkinson10, SE Bartlett11, RM Swift2, A Bonci12 and L Leggio1,3
The corticotropin releasing factor (CRF) exerts its effects by acting on its receptors and on the binding protein (CRFBP), and has
been implicated in alcohol use disorder (AUD). Therefore, identiﬁcation of the exact contribution of each protein that mediates CRF
effects is necessary to design effective therapeutic strategies for AUD. A series of in vitro/in vivo experiments across different species
were performed to deﬁne the biological discrete role of CRFBP in AUD. First, to establish the CRFBP role in receptor signaling, we
developed a novel chimeric cell-based assay and showed that CFRBP full length can stably be expressed on the plasma membrane.
We discovered that only CRFBP(10 kD) fragment is able to potentiate CRF-intracellular Ca2+ release. We provide evidence that
CRHBP gene loss increased ethanol consumption in mice. Then, we demonstrate that selective reduction of CRHBP expression
in the center nucleus of the amygdala (CeA) decreases ethanol consumption in ethanol-dependent rats. CRFBP amygdalar
downregulation, however, does not attenuate yohimbine-induced ethanol self-administration. This effect was associated with
decreased hemodynamic brain activity in the CRFBP-downregulated CeA and increased hemodynamic activity in the caudate
putamen during yohimbine administration. Finally, in alcohol-dependent patients, genetic variants related to the CRFBP(10 kD)
fragment were associated with greater risk for alcoholism and anxiety, while other genetic variants were associated with reduced
risk for anxiety. Taken together, our data provide evidence that CRFBP may possess both inhibitory and excitatory roles and may
represent a novel pharmacological target for the treatment of AUD.
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INTRODUCTION
Stress plays an important role in the development and
maintenance of alcohol use disorder (AUD).1 In response to stress,
corticotropin releasing factor (CRF) activates the hypothalamic−
pituitary− adrenal axis (HPA), leading to the subsequent release of
glucocorticoids.2 Additionally, CRF mediates behavioral responses
to stress via extrahypothalamic regions. CRF exerts its effects via
binding to its receptors (CRFR1 and CRFR2), and to the 37 kD CRF
binding protein (CRFBP).3 Compared to CRF and its receptors,
CRFBP has been much less investigated. This is due to the lack of
control of spontaneous CRFBP proteolytic cleavage that yields a
N-terminal fragment (27 kD) and a C-terminal fragment (10 kD),
and the difﬁculty of purifying large-enough quantities of CRFBP
37 kD full length (FL) for in vitro and in vivo experiments.4
Early preclinical studies showed that CRFBP is expressed in the
cerebral cortex, subcortical limbic structures and anterior pituitary
corticotropes, suggesting that CRFBP plays a critical role in
modulating endocrine and behavioral responses to stress.5 Recent
evidence shows that CRFBP and CRFR2α co-exist in rat ventral
tegmental area (VTA) glutamatergic/GABA synaptosomes that
originate from hypothalamic areas.6 Using microinjection of the
CRFBP antagonist CRF6− 33 in the VTA, it was also demonstrated
that CRFBP, via CRFR2, has a pivotal role in escalation of ethanol
drinking.7 In line with this recent study, earlier work demonstrated
that CRF-mediated cocaine positive reinforcement is associated
with CRFBP and CRFR2 interaction in the VTA dopamine system.8
All these data support our hypothesis that CRFBP is not only a
sequestering protein, but it may possess additional functions. Our
previous electrophysiology work demonstrated that in the VTA
CRF modulates neuronal excitability, through CRFBP and CRFR2
interactions, by potentiating N-methyl-D-aspartate-mediated exci-
tatory postsynaptic currents.9 Therefore, elucidation of the
selective molecular functional of CRFBP and its interaction with
CRFR2 may help us understand the mechanisms underlying
the role of CRFBP in alcohol consumption, thus facilitating the
potential development of effective treatments targeting the
CRFBP in AUD.
MATERIALS AND METHODS
Subjects
All animal procedures were approved by the Ernest Gallo and Clinical
Center Institutional Animal Care and Use Committee, were in accordance
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with NIH guidelines for the Humane Care and Use of Laboratory Animals,
and were conducted in agreement with the Guide for the Care and Use of
Laboratory Animals, National Research Council, 1996. Human subject data
were collected according to screening and assessment NIAAA protocols
approved by the appropriate NIH institutional review boards. All
participants provided written consent before participating. Subjects’
description is detailed in the Supplementary information.
Procedures
Transfection and expression of human cells with the CRFBP-CRFRs chimera.
The plasmids containing the CRFBP-CRFRs, detailed in Supplementary
information, were transfected into HEK293 cells to verify expression of the
protein, conﬁrm appropriate insertion into the membrane, and determine
the functionality of the chimera. Prior to transfection, human cells were
placed in a six-well plate, with DMEM and 10% fetal bovine serum in each
of the wells, and checked for 90–95% cell conﬂuency. The media was
aspirated from the wells and replaced with fresh DMEM/10% fetal bovine
serum. The ﬁnal DNA plasmid preparation was then diluted in Opti-MEM
reduced serum. Lipofectamine 2000 was mixed in Opti-MEM and
incubated at room temperature for 5 min, and then combined with the
diluted DNA. Cell selection, ﬂow cytometry, immunoﬂuorescence, image
analysis, quantiﬁcation of receptors’ surface expression and ﬂuorescence-
based Ca2+ assay are described in the Supplementary information.
Lentivirus expressing shRNA targeting CRHBP. We designed three sets of
shRNAs corresponding to different regions on the CRHBP mRNA sequence
and cloned DNA oligonucleotides encoding the shRNAs into the lentiviral
vector pLL3.7,10,11 which also expresses GFP. pLL3.7 is available from the
plasmid repository Addgene (Cambridge, MA, USA, plasmid #11795). The
shRNA sequences are designated by the number of the ﬁrst base of the
19-nucleotide targeting sequence in rat CRHBP (NCBI NM_139183.2): 1050
(5′-GAAACAGCATCCCGGAGTA-3′), 937 (5′-GAAAATTAGCTGCGACAAT-3′)
and 240 (5′-GCGCCAATTTGAAGCGGAA-3′). As a control, we used a
sequence that did not recognize any known mammalian gene in a BLAST
search (Scr, 5′-GCGCTTAGCTGTAGGATTC-3′). Lentivirus was produced
using the ViraPower Lentiviral Packaging Mix (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). Viral titers were determined by p24 enzyme-linked
immunosorbent assay (Zeptometrix, Buffalo, NY, USA) and were
~ 8× 107 pg ml− 1 for viruses encoding control and CRHBP shRNAs. The
knockdown efﬁciency, intra-amygdala infusion of lentivirus, rats’ self-
administration apparatus and training are described in the Supplementary
information.
Drinking in the dark procedure. Male, mixed-genetic-background (C57BL/
6/SV129 mix) mice were all weaned at P21 and entered in the drinking-in-
the-dark (DID) cycle protocol at greater than 6 weeks of age. After a 2-week
acclimation period, CRHBP− /− and CRHBP+/+ littermates were given
access to one bottle of 20% (v/v) ethanol for 2 h, for three consecutive days;
access began 3 h into the dark cycle. On the fourth consecutive day, mice
were given access to one bottle of 20% (v/v) ethanol for 4 h. The procedure
was repeated each week, with 3 days between cycles. This DID procedure was
used due to the high intake of ethanol on the fourth day of access.12
fMRI protocol. To determine if local knockdown of amygdala CRHBP by
RNA interference produces functional differences compared to control rats,
we measured the hemodynamic activity related to neural activity by
blood-oxygen-level dependence after pharmacological stimuli (yohimbine)
using functional magnetic resonance imaging (fMRI). In brief, during the
magnetic resonance imaging (MRI) scan, after intraperitoneal (i.p.) saline
infusion, all animals received yohimbine (i.p. 2 mg kg− 1, vol. 5 ml kg− 1).
Data acquisition and post-processing are described in the Supplementary
information.
Data analysis
Distributional characteristics of outcome measures were examined to
evaluate similarity to the normal distribution. The Generalized Estimating
Equation (GEE) model was utilized to analyze the drinking behavior of all
animals and to compare the hemodynamic activity between CRHBP shRNA
rats and Scr shRNA rats. GEE was chosen because it can handle
unmeasured dependence when outcomes are repeated measures. We
selected GEE over repeated-measures analysis of variance because it can
more ﬂexibly handle a number of data needs (for example, missing data,
assumed auto correlation structure).
In the GEE model, for the CRHBP-deﬁcient mice analysis was included
the main effect of genotype (CRHBP− /− mice compared to CRHBP+/+
littermates), main effect for time, deﬁned as the six ethanol exposures in
the DID paradigm, and ﬁnally genotype × time interaction. For the CRHBP
knockdown rats in the ethanol self-administration procedure, the GEE
model included the main effect of CRFBP downregulation by shRNA
(CRHBP shRNA compared to Scr shRNA), main effect of time, deﬁned as the
25 ethanol exposures in the operant chamber after surgery, and ﬁnally
shRNA× time interaction. For the fMRI procedure using CRHBP knockdown
rats, the GEE model included the main effect of shRNA, main effect of
yohimbine (compared to saline), main effect of time, deﬁned as the time
during the fMRI procedure comprised by saline (20.8-41.5 min) and
yohimbine (41.6-62.4 min) infusion corrected from baseline (0-20.7 min),
and shRNA× yohimbine interaction. The same model was used to analyze
center nucleus of the amygdala (CeA), paraventricular nucleus (PVN) and
caudate putamen. Post hoc analysis was used to assess speciﬁc time-point
differences over time and P-values were Bonferroni corrected for multiple
comparisons. In CRHBP− /− mice and their CRHBP+/+ littermates, unpaired
t-test was utilized to measure blood ethanol content level, water or sucrose
consumption on day 4, the amount of pro-CRF to detect the differences
among genotypes in the PVN and CeA. In the CRHBP shRNA analysis,
unpaired t-test was utilized to analyze the in vitro downregulation, rats’
ethanol self-administration after recovery from surgery, and hemodynamic
activation between saline and yohimbine infusion. Also, for Ca2+ assay
signaling, comparisons between groups were performed using unpaired t-
test. Pearson correlation was utilized to evaluate ethanol consumption and
blood ethanol content.
Allele frequencies and genetic association analyses in humans were
conducted using PLINK v1.07.13 Association with alcohol dependence
diagnosis was tested using logistic regression and an additive genetic
model. Further tests were conducted to evaluate associations with alcohol
drinking and anxiety phenotypes in alcohol dependent individuals using
linear regression. All models were conducted in the full sample, as well as
split by European and African ancestry based on subject self-report. Age,
gender, and ancestry informative marker scores for European and African
ancestry were included as covariates in all models, even when split by
ancestry; total score from the Childhood Trauma Questionnaire was also
included as a covariate in the linear regression models for drinking and
anxiety outcomes.
Results are reported as mean (M) and error bars indicate standard error
(s.e.m.). All statistical tests were two-sided, and statistical signiﬁcance was
accepted if a *P-value o 0.05 was obtained. SPSS (v.22) (Armonk, NY, USA)
was used to conduct the analysis and GraphPad Prism (v.5) was used to
generate ﬁgures (La Jolla, CA, USA).
RESULTS
CRFBP(FL) and its fragments, CRFBP(27kD) and CRFBP(10 kD), are
stably expressed on the plasma membrane of both CRFR2α and
CRFR1
Purifying human CRFBP or its fragments in sufﬁcient quantities for
investigation has not been successful to date. The precise
mechanism that promotes CRFBP(FL) cleavage into two frag-
ments, CRFBP(27kD) and CRFBP(10 kD), is still under investigation.4
Our goal was to have CRFBP(FL) and its fragments stably
expressed and maintained in close proximity to the receptors in
order to determine whether they modulate the receptors’
signaling. To achieve this expression, we created six covalently
linked polypeptides between CRFBP, and its fragments, to the
receptors. We fused FLAG-tagged CRFBP(FL), CRFBP(27kD) or
CRFBP(10 kD) with HA-tagged CRFR1 or HA-CRFR2α and cloned
these into a pCDNA3.1-based mammalian expression vector
(Figure 1a). Constructs were veriﬁed by sequencing, protein
integrity was veriﬁed by western blot (Figure 1b, Supplementary
Figure S1a) and protein expression was conﬁrmed using
immunoﬂuorescence: FLAG-CRFBP(10 kD)-HA-CRFR2α (Figure 1c,
Supplementary Movie S1), FLAG-CRFBP(FL)-HA-CRFR1, FLAG-CRFBP
(FL)-HA-CRFR2α, FLAG-CRFBP(27kD)-HA-CRFR1, FLAG-CRFBP
(27kD)-HA-CRFR2α and FLAG-CRFBP(10 kD)-HA-CRFR1
(Supplementary Figure S1b). We also co-transfected FLAG-CRFBP
(10 kD) (Figure 1d), FLAG-CRFBP(FL) and FLAG-CRFBP(27 kD)
(Supplementary Figure S1c) with HA-CRFRs into HEK293 cells as
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an additional control, to verify that CRFBP and its fragments, when
not tethered to either CRFRs, were expressed intracellularly in
regulated secretory pathways and did not interact with the
receptors on the cell membrane.
Only CRFBP(10 kD)-CRFR2α can potentiate CRF-induced CRFR2α
signaling
Next, we examined the functional properties of the covalently
linked polypeptides created from CRFBP. We tested the ability of
the chimeric proteins to activate intracellular calcium (Ca2+)
release to evaluate if they are capable of producing CRF-induced
receptor signaling. Full-dose response curves were generated for
CRF-induced release of intracellular Ca2+ at all chimera proteins
and compared with HA-CRFR-only transfected cells. From compar-
ison of the Emax values, we determined that only FLAG-CRFBP
(10 kD) when tethered to HA-CRFR2α potentiates CRF-induced
signaling, when compared to the CRFR2α-only signal (Figure 2a).
The activation by CRFBP(10 kD) via CRFR2α, which leads to
increased signaling in response to CRF, was unique to the
combined action of CRFR2α tethered to the CRFBP(10 kD)
fragment, was not mimicked by the other chimeric proteins
(Supplementary Figures S2a–c), and it was not due to the different
levels of functional protein delivered to the cell surface
(Figure 2b). In particular, CRF binds both CRFR1 and CRFR2α, but
is more potent at CRFR1.14–17 Interestingly, there is ample
evidence that CRFR1 is associated with anxiety-related
behaviors.18,19 In light of this, we examined whether the observed
enhancement of the CRFBP(10 kD) chimeric complex signaling
was speciﬁc to CRFR2α or whether the expression of CRFR1 would
also increase signaling in a chimeric protein when tethered with
CRFBP(10 kD). As expected, CRF induced a potent release of
intracellular Ca2+ at CRFR1; however, there was no enhancement
of CRF-induced signaling at both the CRFBP(10 kD)-CRFR1 and
CRFBP(27kD)-CRFR1 chimeric proteins (Supplementary Figure S2b).
In additional control experiments, CRF-mediated Ca2+ signaling
was absent in any FLAG-CRFBP-only transfected cells, and in non-
transfected HEK293 cells, which do not express endogenous
CRFR1 or CRFR2α (Supplementary Figures S2d–h). To further test
the full functionality of the FLAG-CRFBP(10 kD)-HA-CRFR2α
chimeric protein, we examined whether it can be also inhibited
by the CRFR2 antagonist antisauvagine (AS-30). The Ca2+ assay
experiment demonstrated that the increase in intracellular Ca2+
release elicited by 1 μM CRF (EC80) was dose-dependently inhibited
by AS-30 (IC50) (Figure 2c).
Finally, the complete functionality of FLAG-CRFBP(10 kD)-HA-
CRFR2α chimera was tested by evaluating its post-endocytic
behavior. A three-dimensional (3D) confocal analysis showed
chimeric receptors were distributed in the plasma membrane and
projected outward from ﬁnite regions of the membrane of the
transfected cells (Figure 2d). When cells transfected with FLAG-
CRFBP(10 kD)-HA-CRFR2α were left untreated, there was no
signiﬁcant receptor internalization. CRF-induced internalization
of FLAG-CRFBP(10 kD)-HA-CRFR2α was inhibited by pretreatment
with the CRFR2 selective antagonist AS-30.
Figure 1. The CRFBP(10 kD)-CRFR2α chimeras are expressed on the plasma membrane of HEK293 cells. (a) Schematic representation of the
FLAG (DYKDDDDK epitope)-tagged CRFBP with hemagglutinin (HA)-tagged corticotropin releasing factor receptors (CRFRs) cloned into
pCDNA3.1-based mammalian expression vector. (b) Western blot analysis of FLAG-CRFBP(10 kD)-HA-CRFR2α chimeric constructs. The blots
were probed with primary antibody: anti-CRFBP C-19 (1:100) or anti-HA.11 (1:1000), then probed with secondary antibody: donkey anti-goat
(IgG-HRP) (1:5000) to visualize CRFBP, or goat anti-mouse (IgG H+L-HRP) (1:5000) to visualize the receptors. Lane 1: HEK293 cells (negative
control), lane 2: FLAG-CRFBP(10 kD) (MW~10 kD) (positive control), lane 3: FLAG-CRFBP(10 kD)-HA-CRFR2α (MW~60 kD), lane 4: FLAG-CRFBP
(10 kD)-HA-CRFR2α (MW~60 kD). Immunohistochemical staining of HEK293 cells: (c) transfected with FLAG-CRFBP(10 kD)-HACRFR2α showing
CRFBP(10 kD) stably expressed on the cell membrane and co-expressed with CRFR2α. The cells were ﬁxed and permeabilized and then probed
with anti-FLAG antibodies for FLAG-CRFBP(10 kD) and visualized using AlexaFluor-488 conjugated anti-mouse (IgG2a) secondary antibody, or
probed using anti-HA and visualized using AlexaFluor-594 conjugated anti-mouse (IgG1) antibody and merged ﬂuorescent image with 4`,6-
diamidino-2-phenylindonle (DAPI) to visualize the nuclei; (d) co-transfected with CRFBP(10 kD) with HA-CRFR2α, which does not interact with
the receptor at the plasma membrane. FLAG-CRFBP(10 kD) visualized using AlexaFluor-488 conjugated anti-mouse (IgG2a) secondary antibody
was co-transfected into HEK293 cells with HA-CRFR2α, probed using anti-HA, and visualized using AlexaFluor-594 conjugated anti-mouse
(IgG1) and merged ﬂuorescent image with DAPI to visualize the nuclei. Scale bar, 5 μM.
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Higher ethanol consumption in CRHBP− /− mice compared to
their CRHBP+/+ littermates
To investigate the in vivo role of CRFBP in binge-like alcohol
consumption, we tested the well-validated CRHBP-deﬁcient (− /− )
mouse model 20 with the DID procedure using a 6-week
paradigm.12 Wild-type (CRHBP+/+) littermates, used as control,
underwent the same procedures. There was a signiﬁcant main
effect of genotype in increasing ethanol consumption in the
CRHBP− /− mice, compared to CRHBP+/+ littermates during the 4-
h period on day-4 of ethanol access (Figure 3a, Supplementary Table
S1). There were no main effects of time; however, we found a trend
of genotype× time interaction. Post hoc analysis revealed that
ethanol consumption increased after repeated DID exposure, with
a strong effect at the 6-DID cycle.
There was no difference between genotypes in 5% (v/v) sucrose
consumption in the DID model (Figure 3b), nor in total water
consumption during the 21-hour period when mice were not
exposed to ethanol (Figure 3c). Furthermore, consistent with
previous DID studies,12 there was a linear correlation between
ethanol intake and blood ethanol content in both genotypes. At
baseline, the two genotypes consumed similar amounts of ethanol
and we found no difference in blood ethanol content between
CRHBP− /− and CRHBP+/+ littermates (Supplementary Figures
S3a and b). To evaluate if there were CRF compensatory effects in
the CRHBP− /− mice, we measured the amount of CRF from brain
homogenates in the PVN of the hypothalamus and in the CeA.
Western blot of pro-CRF expression in the PVN, where CRF is
synthesized,21 and in the CeA, where it is highly expressed,22 at
week 1 of the DID procedure in ethanol naive mice showed no
signiﬁcant difference between the genotypes (Supplementary
Figure S3c). Taken together, these results indicate that there were
no baseline compensatory effects in CRHBP− /− mice that might
account for the difference in ethanol consumption compared to
wild-type littermates.
Figure 2. The CRFBP(10 kD)-CRFR2α chimeras potentiate CRF-induced release of intracellular Ca2+. (a) Full-dose response curves were
generated for CRF-induced release of intracellular Ca2+ at the CRFBP(10 kD)-CRFR2α chimera (EC50= 385± 4.0 nM) compared with CRFR2α-
only transfected cells (EC50= 99± 8 nM). From comparison of the Emax values, we determined that CRFBP(10 kD), when tethered to CRFR2α
(Emax= 2520± 85 RFU), potentiates CRF-induced signaling when compared to the CRFR2α-only signal (Emax= 930± 81 RFU, ***P40.05). (c) The
CRFR2 antagonist, antisauvagine-30 (AS-30, 1 pm− 10 μM), inhibits CRF (1 μm)-induced intracellular calcium release in HEK293 cells stably
expressing FLAG-CRFBP(10 kD)-HA-CRFR2α (IC50= 5 3± 0.4 nM). (d) Immunocytochemical analysis of receptor trafﬁcking. Cells were left
untreated (NT); treated with the agonist (CRF) for 30 min (1 μM, promoted endocytosis of CRFR2α and the extracellular receptors were
contracted); pretreated with CRFR2 selective antagonist AS-30 for 30 min (1 μm) and then treated with agonist (CRF). Antagonist with AS-30
reduced CRF-induced endocytosis; cells showed no signiﬁcant difference in receptor contraction compared to cells left untreated. Scale bar,
5 μM. Results are expressed as M± s.e.m., relative ﬂuorescence units (RFU), calculated as agonist-induced maximum calcium peak/cell
number × 1000. CRFR, corticotropin releasing factor receptor.
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CRFBP downregulation in the CeA reduces ethanol
self-administration and CeA hemodynamic activity, but does not
attenuate yohimbine-induced ethanol self-administration
Previous studies have reported human (h)CRFBP mRNA and
protein level in rat brain5 and dense hCRFBP-stained terminal
ﬁelds in the CeA of human brain.23 However, very little is known
about the mechanism and molecular network that underpin the
stress-related functions mediated by CRFBP in the CeA, a limbic
region that controls emotionality and alcohol reinstatement.24,25
Therefore, to investigate the causal link between CRFBP in the CeA
and alcohol-seeking behaviors, we utilized a rat model trained to
self-administer ethanol, designed with controlled regional expres-
sion of CRFBP. Sequences encoding small hairpin RNAs (shRNAs)
targeting CRHBP were cloned into a lentiviral vector. We tested for
the ability of the shRNAs to knock down CRHBP expression in vitro.
We found that CRFBP expression was signiﬁcantly reduced in cells
infected with lentivirus expressing CRHBP shRNA, as compared to
cells infected with the control non-targeting shRNA (Scr)
(Supplementary Figures S4a-c). We then selected the most potent
CRHBP shRNA for in vivo testing. Long-Evans rats trained to self-
administer ethanol were injected bilaterally in the CeA with
lentivirus expressing the CRHBP or the control Scr shRNA. We
conﬁrmed infection in the CeA in vivo by magnetic resonance
imaging scan (Supplementary Figure S4d) and post-mortem by
GFP visualization of infected cells in each animal.
After recovery from surgery, during the subsequent 15 ethanol
sessions, a signiﬁcant shRNA× time interaction was found.
Post hoc analysis indicated that rats infected with CRHBP shRNA
showed a signiﬁcant reduction in ethanol consumption. By
contrast, in the Scr shRNA control rats, there was no statistical
difference between the amount of ethanol consumed at baseline
and the following sessions (Supplementary Figure S4E). Reduction
of CRFBP expression in the CeA did not however attenuate
yohimbine-induced ethanol drinking, as both CRHBP shRNA and
Scr shRNA rats increased ethanol consumption after yohimbine i.p.
administration. Taken together, these results indicate that CRHBP
shRNA rats were unable to return to their baseline self-
administration drinking behaviors. However, this effect disap-
peared after administering a pharmacological stressor via a
yohimbine challenge.
To further validate the in vivo downregulation of CRFBP and the
effect of yohimbine administration, we evaluated intrinsic brain
excitability using blood-oxygen-level dependence, a measure of
neural hemodynamic activity. During the magnetic resonance
imaging scan, after a baseline assessment, all animals received a
saline, followed by a yohimbine, i.p. infusion25 (Figure 4a and b).
To make a mechanistic link between the effect of CRFBP
knockdown in the CeA and ethanol self-administration, we
analyzed other brain regions that are known to show activation
during yohimbine administration. Yohimbine produced a compo-
site pattern of blood-oxygen-level dependence % signal change
between the CRHBP and the Scr shRNA rats in the limbic,
hypothalamic and subcortical areas (Figure 4c and d). We found a
main effect of yohimbine in the caudate putamen and a trend in
the PVN. There was no main shRNA effect or yohimbine × shRNA
interaction in these brain regions. In the CeA, there was a lower
hemodynamic activation in CRHBP shRNA rats compared to
controls. Furthermore, when we compared the shRNA rats (CRHBP
vs Scr) and condition (saline vs yohimbine) effects, we found a
main signiﬁcant effect of yohimbine and a shRNA× yohimbine
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Figure 3. Ethanol consumption is signiﬁcantly higher in CRHBP− /− mice compared to their CRHBP+/+ littermates in the drinking in the dark
(DID) procedure. (a) During the 4-h period on day 4, there was a signiﬁcant main effect of genotype (CRHBP− /− vs CRHBP+/+; n = 17− 16,
respectively; B = 0.977, *P o 0.05), no main effect of time (n = 17− 16, P40.05), but a trend of genotype × time interaction (n = 17− 16, B1
= 0.289, P = 0.073) with ethanol consumption increased after repeated DID exposures and a strong effect at the sixth DID cycle. There
was no difference in (b) 5% (v/v) sucrose consumption (CRHBP− /− vs CRHBP+/+; n = 10− 4, P40.05) and (c) total water consumption
(CRHBP− /− vs CRHBP+/+; n = 8− 3, P40.05), between the CRHBP− /− mice and their CRHBP+/+ littermates. Results are reported as
M± s.e.m.; not signiﬁcant (P 4 0.05).
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interaction. Post hoc analyses revealed that there was no
difference in CeA activation between saline and yohimbine
infusion in the CRHBP shRNA rats (Figure 4e). By contrast, as
expected, there was a signiﬁcant difference in CeA activation
between saline and yohimbine infusion in the control Scr shRNA
rats (Figure 4f).
Human genetic association study of CRFBP(10 kD) candidate gene
variants in alcoholic individuals
Consistent with previous rodent work, the in vivo experiments
above indicate a role of CRFBP in alcohol-seeking behaviors.
Furthermore, the in vitro chimeric work demonstrates a peculiar
role of the CRFBP(10 kD) fragment in potentiating CRF signaling.
Finally, a human genetic study was conducted in order to provide
preliminary translation of these in vivo and in vitro ﬁndings.
We a priori selected single-nucleotide polymorphisms (SNPs) of
the CRHBP gene that are located in gene regions related to CRFBP
(10 kD), an approach driven by the chimeric results reported
above and were investigated for possible association with
alcoholism in previous studies,26,27 an approach driven by the
rodent results reported above. This approach led to the selection
of three SNPs located in the CRFBP(10 kD) gene regions:
rs10055255 and rs10062367, which were previously evaluated in
stress-induced alcohol craving in heavy drinkers;26 and rs7728378,
which was previously investigated in Caucasian alcohol
dependent individuals.27 Notably, the latter SNP was associated
with suicide attempt in another study of patients with alcohol and
substance dependence.28 Only rs10062367 was present in our
dataset. For the other two SNPs, we were able to identify proxies
(rs1053989 and rs7718461) in high linkage disequilibrium, in both
the European and African subsamples (an important aspect given
that the dataset includes approximately 60% Caucasians and 40%
African Americans, Supplementary Table S2).
While there were no differences in the prevalence of these three
SNPs analyzed between alcohol dependent patients and controls
(data not shown), the rs10062367 A allele showed a signiﬁcant
association with average drinks per drinking day, both in the full
sample as well as in the African ancestry subgroup. Associations
between the three SNPs and alcohol phenotypes in subjects with
current alcohol dependence are summarized in Table 1 and allele
frequencies in Supplementary Table S3. For the anxiety measures,
there was a signiﬁcant main effect of rs10062367 A allele for
the State-Trait Anxiety Inventory anxiety in European ancestry.
We found a signiﬁcant effect of rs7718461 A allele for the
Comprehensive Psychopathological Rating Scale anxiety in
European ancestry, and a negative association with this scale
anxiety in European ancestry. There was a signiﬁcant effect of
rs1053989 C allele for the Comprehensive Psychopathological
Rating Scale anxiety in the European ancestry. Finally, we found a
signiﬁcant effect for neuroticism in the European ancestry. These
Table 1. Associations between SNPs, alcohol- and anxiety-related phenotypes in subjects with alcohol dependence
SNP Allele N β P Ancestry Score Risk
rs10062367 A 467 1.310 0.02286 Full TLFB Increased
206 1.616 0.04844 African TLFB Increased
86 4.034 0.04699 European STAI anxiety Increased
rs7718461 a A 220 − 1.457 0.01491 European CPRS anxiety Reduced
rs1053989 b C 223 − 2.050 0.03561 European Neuroticism Reduced
221 − 0.298 0.03035 European CPRS anxiety Reduced
Abbreviations: CPRS, Comprehensive Psychopathological Rating Scale; SNP, single-nucleotide polymorphism; STAI, State-Trait Anxiety Inventory; TLFB, alcohol
time life followback average drinks. aProxy for rs7718461. bProxy for rs10055255.
Figure 4. Brain hemodynamic activity in the center nucleus of the amygdala (CeA) downregulated CRFBP in rats trained to self-administer
ethanol. CRHBP short hairpin RNA (shRNA) (upper panel) and Scr shRNA (lower panel). (a, b) CeA bilateral representative functional magnetic
resonance imaging scans of Scr shRNA controls and CRHBP shRNA rats. Timeline (green line) and pharmacological experimental manipulation
(black: baseline; blue: saline; red: yohimbine). (c, d) We found a strong main effect of yohimbine in the caudate putamen (n= 6 each group,
B1=− 0.801, ***Po0.001) and a trend of main effect of yohimbine in the PVN (n = 6 each group, B1 = 0.8876, P = 0.069). There was no main
shRNA effect or yohimbine × shRNA interaction for these outcomes. In the CeA, when we compared the shRNA rats and condition (saline and
yohimbine) effects, we found a main signiﬁcant effect of yohimbine (n= 6 each group, B1 = 1.125, *P o 0.05) and a shRNA× yohimbine
interaction (n = 6 each group, B 1= − 2.372, *P o 0.05). A Bonferroni post hoc analysis revealed that (e) in the CRHBP shRNA rats there was no
difference in CeA activation between saline and yohimbine infusion (Pcorrected4 0.05), but (f) there was a stronger activation in the control Scr
shRNA rats (t1499 = 2.511, ***Pcorrected o 0.001). Coronal sections are presented from their antero-posterior orientation. Results are reported
as M± s.e.m..; not signiﬁcant (P 4 0.05). PVN, paraventricular nucleus.
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results suggest the possibility that variation of the CRFBP(10 kD)
protein might alter the risk of alcohol drinking and/or anxiety in
alcohol-dependent patients.
DISCUSSION
Using a combination of different in vitro, in vivo, rodent and
human studies, our work represents a comprehensive translational
effort to deﬁne the discrete biological role of CRFBP. Our results
provide converging evidence supporting the role of CRFBP in
alcohol consumption.
First, we sought to establish a CRFBP role in CRF-receptor
signaling. Here we describe a novel approach where, by tethering
human CRFBP with its receptors, we were able to express it at the
cell surface and evaluate if CRFBP participates in CRF signaling. We
discovered that only CRFR2α is involved in the CRF-mediated
receptor activation in the presence of CRFBP. This observation is
consistent with our previous electrophysiological work showing
that CRF selectively increases N-methyl-D-aspartate currents via
CRF interaction with CRFR2α and CRFBP.9 Furthermore, our results
are in line with more recent work demonstrating that CRFBP
interacts with CRFR2α and increases receptor expression on the
cell surface.29 The chimeric receptor approach allowed us to study
not only the native protein, but also its fragments. Receptor signal
response was detected only when CRFBP(10 kD) was tethered to
CRFR2α. By creating a series of chimeric receptors tethered to
individual CRFBP fragments, we discovered a potential activating
role of the CRFBP(10 kD), speciﬁcally via CRFR2α signaling, that
would not have been discovered without this approach. The fact
that CRFBP(10 kD) tethered to CRFR2α was able to potentiate
receptor signaling indicates that CRFBP(10 kD) may play a role
in vivo. We propose that CRF interacts with CRFBP(10 kD) and
CRFR2α in an allosteric manner since CRFBP(27kD) retains the
active picomolar afﬁnity binding site for CRF.30 As such, our results
suggest a potential dual action of CRFR2α and CRFR1 during stress
maladaptation, as was previously postulated.31 Genetic and
pharmacological manipulations targeting CRFR2 have shown that
CRF may lead to either increased or decreased response to
stressors.32 In normal conditions, CRF signal via CRFR133 and
CRFBP, in its protecting role, binds the extra unbound CRF.30
However, during maladaptive stress induction, CRFBP(27kD)
cannot sequester the excess of ‘free’ CRF, while CRFBP(10 kD)
allosterically potentiates CRFR2α signaling. CRFBP is a critical
component of the CRF system, yet its speciﬁc physiological role
has not been elucidated, mostly because of the difﬁculty in
purifying a large-enough quantity for experimental design.4 Our
approach is not intended to show that the covalently linked
CRFBP-CRFR2α mimics in vivo physiological conditions. Rather, this
translational approach provides, to the best of our knowledge, the
ﬁrst novel screening assay to identify non-peptidic chemical
inhibitors that disrupt the CRFR2α activation in the presence of
CRFBP. Our data show an enhancing role of CRFBP and CRFR2α
interaction in the central nervous system, a ﬁnding consistent with
recently reported molecular,29 and our original electrophysiology,9
data. The coexistence of CRFBP and CRFR2α in glutamatergic/
GABA synaptosomes6 also supports our ﬁndings, as well as
independent work suggesting that CRFBP may possess a
facilitatory effect on administration of cocaine8 and ethanol.7
Our chimeric results provide additional evidence to previous work
indicating that (1) CRFBP possesses both a sequestering and a
potentiating role for CRF;34 (2) CRFR2α may play a role in the
regulation of stress response;35 and (3) ‘free’ CRF alone does not
necessarily predict stress response.23
Previous work showed that CRF is a modulator of ethanol
drinking within the DID paradigm.36–38 In the present work, we
evaluated the in vivo role of CRFBP in binge-like ethanol
consumption. For this purpose, we utilized the CRHBP− /− mouse
integrated in the DID procedure, a validated procedure to study
the transition to ethanol dependence. Consistent with the previous
characterization of CRHBP− /− mice,39–42 our results indicated that,
in the absence of the CRFBP, higher levels of unbound CRF increase
CRFR activation, leading to increased ethanol consumption in the
CRHBP− /− mice. Our results extend previous ﬁndings demonstrat-
ing an important role of CRFBP in attenuating the neural responses
produced by continuous exposure to stress insults.30 These
observations are further corroborated, ﬁrst by a signal detected in
the genotype× time interaction. Then, a post hoc analysis revealed
that CRHBP− /− mice compared to the CRHBP+/+ littermates
showed increased ethanol consumption after 6-DID exposures.
While CRF involvement was not tested directly and is a recognized
limitation of this study, we speculate that our results are CRF-
mediated as they corroborate previous work using the DID
paradigm, where ethanol intake enhances CRF function in the
CeA, and systemic, intracerebroventricular and intra-amygdalar
administration of CRFR1 antagonist reduces DID intake.32,36,37,43,44
In line with these results, we found here the increase of ethanol
drinking behavior observed in CRHBP− /− mice after the repeated
DID cycle is most likely the result of increased unbound CRF in the
brain of CRHBP-deﬁcient animals, rather than a basal down-
regulation of CRF synthesis measured in the CeA and PVN, or an
alteration of ethanol metabolism. Our western blot analysis, in
ethanol naive mice, are consistent with the recent published data
on CRF mRNA levels in CRHBP− /− mice and their littermates.45
Together, these results support a contribution of CRFBP in ethanol
consumption in mice, and raise the possibility that CRFBP
imbalance contributes to binge drinking.
CRF mediates behavioral responses to stress and ethanol
consumption in extra-hypothalamic regions, including the CeA.24
The in vivo function of CRFBP in regulating neuronal activity in
circuits involved in addiction has been poorly understood due to
the instability of CRFBP in vitro and the lack of pharmacological
probes. Thus, in order to determine the mechanistic role of CRFBP
in extrahypothalamic regions and its effect on ethanol-seeking
behavior, we hypothesized that downregulation of CRHBP in the
CeA modulates excitatory behavioral outcomes. This was based on
the observation that the CeA is a limbic brain region known to be
important for modulation of stress activation where CRHBP is
highly expressed.22 Reduced CRHBP levels in the CeA resulted in
lower drinking in the ethanol operant self-administration proce-
dure; however, the reduction of ethanol consumption did not
persist after a yohimbine challenge. Our results suggest that
downregulating CRFBP regional expression, by knocking down
CRFBP in the CeA, was sufﬁcient to blunt the ethanol drinking-
behavioral phenotype per se. However, it is not sufﬁcient to
control drinking during activation of the brain norepinephrine
system. Consistent with this hypothesis, our fMRI data showed
that other known brain regions activated by yohimbine and
sensitive to norepinephrine stimulation (caudate putamen and
PVN studied here) are activated, and they may be responsible for
the increase of ethanol consumption. Viral infusion into the CeA
selectively altered the reactivity to yohimbine in this area, but not
in other brain structures in CRHBP knockdown rats, probably
because shRNA CRHBP only downregulated CRFBP expression (by
50%), resulting in conﬁned reduction of metabolic activation in
the CeA without affecting other brain areas with strong
connectivity. These observations are in line with recent results
demonstrating that microinjection of CRFBP antagonist CRF6-33
into the CeA does not change alcohol intake, while CRFBP in the
VTA may be responsible for escalation of ethanol drinking.7
Our ﬁnal goal was to provide initial translational evidence of our
ﬁndings. While the covalently linked CRFBP-CRFR2α does not
represent an in vivo physiological condition, our in vitro chimeric
work guided us in narrowing down the SNP selection from 322 to
88 amino-acid residues. We showed that rs10062367 A seems to
be a risk allele, as it was associated with increased average drinks/
day and an increased anxiety trait. These data are not consistent
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with previous work26 where rs10055255, but not rs10062367, was
associated with alcohol- and stress-related phenotypes. However,
several factors may explain the differences in these results, for
example, differences in the size of the two samples, race- and
ethnicity-related differences, and different instruments used to
assess the outcomes of the two studies. On the other hand,
consistent with the other previous studies,26,27 we found that
rs7718461 A and rs1053989 C alleles were associated with lower
neuroticism and anxiety (reduced risk). However, it is important to
note that the SNPs analyzed here are all located in the intronic
portion of the gene, which suggests that they might not have
functional signiﬁcance. Although the selected SNPs were all
intronic, there are no known SNPs in the gene region encoding for
the CRFBP(10 kD) fragment; some are very rare while others have
extremely low minor allele to allow for properly powered genetic
analyses. Nonetheless, our approach was based on a strong a
priori hypothesis and our results suggest that CRFBP may play a
role in alcohol- and anxiety-related behaviors in alcohol-
dependent patients. Although no case− control differences were
found and the exact functionality of these SNPs remain uncertain,
the present results, together with previous work, suggest a role of
CRFBP in alcohol- and anxiety-related phenotypes in a clinically
relevant sample of individuals with alcohol dependence. Indeed,
the present data represent the largest human study looking at the
genetic variant of the CRFBP gene in alcohol dependence.
In summary, CRFBP has been studied for more than two
decades, and a variety of hypotheses on its physiological role have
been developed. Our ﬁndings suggest that CRFBP may possess a
dual role: CRFBP(27kD) is responsible for neutralizing CRF effects,
while CRFBP(10 kD) has a potential excitatory function. Evaluating
the individual functional interaction of each CRFBP fragment with
each receptor may elucidate many aspects of stress and AUD, and
lead to the development of novel effective treatments.
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